Clinical trials: Tislelizumab
Nasopharyngeal Cancinoma (NPC)
Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial
This study is aimed to evaluate the efficacy and safety of tislelizumab combined with chemotherapy and response-adapted radiotherapy in patients with de novo metastatic nasopharyngeal carcinoma
- Trial name
- NCT07248696
- Testing
- response-adapted radiotherapy
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Chongqing University Cancer Hospital
Rectal Cancer
Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy
This is an open-label, multi-center, single-arm clinical study. All patients received 4-6 cycles total neoadjuvant therapy plus concurrent tislelizumab immunotherapy, then underwent clinical response assessment.
- Trial name
- TNTIT (NCT07561060)
- Testing
- Tislelizumab, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Non-small Cell Lung Cancer Stage III
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy
Patients with stage III non-small-cell lung cancer initially evaluated as unresectable are selected for the program, who are remained unresectable after 2-4 cycles of conversion chemotherapy combined with immune checkpoint…
- Trial name
- NCT06031597
- Testing
- radiotherapy, Platinum-Based Drug, Immunotherapy
- Volunteers
- 105 people
- Sponsor
- Zhejiang Cancer Hospital
Advanced Solid Tumor Cancer, Triple-Negative Breast Cancer (TNBC)
Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease
This study is designed to establish the safety of the combination of PD-1 inhibitor tislelizumab, an anti-angiogenic agent bevacizumab and a chemotherapeutic agent capecitabine, in a phase Ib setting and to evaluate preliminary…
- Conditions
- Advanced Solid Tumor Cancer, Triple-Negative Breast Cancer (TNBC), CNS Disease, Breast Cancer
- Trial name
- TIBEC (NCT07681297)
- Testing
- Tislelizumab + Bevacizumab + Capecitabine
- Where
- Singapore
- Volunteers
- 154 people
- Sponsor
- National University Hospital, Singapore
NK/T Cell Lymphoma
A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma
The goal of this clinical trial is to learn if the regimen of dexamethasone, azacitidine, pegaspargase and tislelizumab (DAPT regimen) combined with radiotherapy works to treat stage I or II NK/T cell lymphoma in adults.
- Trial name
- NCT07000617
- Testing
- DAPT regimen plus radiotherapy
- Where
- 3 sites in China
- Volunteers
- 57 people
- Sponsor
- Peking University Cancer Hospital & Institute
Pulmonary Pleomorphic Carcinoma, Immunotherapy
Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Advanced Pulmonary Pleomorphic Carcinoma
Evaluate the efficacy and safety of tislelizumab in combination with anlotinib in patients with stage III and IV PSC .
- Conditions
- Pulmonary Pleomorphic Carcinoma, Immunotherapy, Tislelizumab
- Trial name
- NCT05375734
- Testing
- Tislelizumab in combination with anlotinib
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Advanced Rectal Cancer, Distal Metastasis
A Combination Therapy Including Anti-PD-1 Immunotherapy in Rectal Cancer With Refractory Distal Metastasis
Though surgical resection remains the primary choice for advanced rectal cancer, about 80% are considered unresectable due to the number, size, or location of metastases.
- Trial name
- Miracle-2 (NCT05359406)
- Testing
- a combination therapy including tislelizumab
- Where
- China
- Volunteers
- 51 people
- Sponsor
- LI XIN-XIANG
NK/T Cell Lymphoma
Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma
The optimal first-line treatment for extra-nodal NK/T-cell lymphoma (ENKTL) has not been well-defined. This phase II study aimed to evaluate the efficacy and safety of Dexamethasone, azacytidine, Pegaspargase, Tislelizumab (DAPT)…
- Trial name
- NCT04899414
- Testing
- Dexamethasone, azacytidine, Pegaspargase, Tislelizumab
- Where
- 3 sites in China
- Volunteers
- 50 people
- Sponsor
- Peking University
Colorectal Cancer
Tislelizumab in People With Colorectal Cancer
The researchers are doing this study to find out whether tislelizumab is an effective treatment for people with colorectal cancer who are living in Nigeria. The researchers will also look at the safety of the study drug.
- Trial name
- NCT06529523
- Testing
- Tislelizumab
- Where
- 3 sites in United States, Nigeria
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Triple-negative Breast Cancer
Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer
This is a multicenter, open-label, single-arm clinical study designed to evaluate the safety and efficacy of surufatinib combined with tislelizumab in the treatment of metastatic triple-negative breast cancer (TNBC).
- Trial name
- NCT05746728
- Testing
- Surufatinib, Tislelizumab
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Huihua Xiong
Resectable Hepatocellular Carcinoma
Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.
This is a phase II prospective study to evaluate the safety and efficacy of Tislelizumab monotherapy or combined with lenvatinib as neoadjuvant therapy for resectable hepatocellular carcinoma.
- Trial name
- NCT05807776
- Testing
- Tislelizumab, Tislelizumab, Lenvatinib
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma
TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and molecular target therapies in patients with advanced-stage…
- Trial name
- CHANCE2201 (NCT05332821)
- Testing
- PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE
- Where
- 2 sites in China
- Volunteers
- 1,244 people
- Sponsor
- Zhongda Hospital
MSI-H/dMMR Solid Tumors
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
In this Phase 2, Single-Arm, Multi-Center, Open-Label Study, participants with previously treated locally advanced unresectable or metastatic solid tumors with mismatched repair deficient (dMMR) or microsatellite instability-high…
- Trial name
- NCT03736889
- Testing
- Tislelizumab (BGB-A317)
- Where
- 29 sites in China
- Volunteers
- 200 people
- Sponsor
- BeiGene
Glioblastoma Multiforme
TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.
The goal of this clinical trial is To investigate the safety and efficacy of Tumor-Treating Fields (TTFields) in combined with temozolomide (TMZ) and tislelizumab in the treatment of newly diagnosed glioblastoma (GBM).
- Trial name
- NCT06353360
- Testing
- Tumor Treating Fields, Tislelizumab, Temozolomide (TMZ)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Peripheral T-cell Lymphoma, NK/T-cell Lymphoma
A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma
This trial is proposed with treatment of ATG-010 combined with chemotherapy regimens which will be chosen by investigators (ICE [ifosfamide+carboplatin+etoposide] or GEMOX [gemcitabine+oxaliplatin] or Tislelizumab), after…
- Trial name
- TOUCH (NCT04425070)
- Testing
- ICE [ifosfamide+carboplatin+etoposide], GEMOX [gemcitabine+oxaliplatin], Tislelizumab
- Where
- 13 sites in China
- Volunteers
- 56 people
- Sponsor
- Antengene Corporation
Hepatocellular Carcinoma
TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma
Most hepatocellular carcinoma (HCC) are found in the intermediate or advanced stage. The patients lose the opportunity of curative surgical resection.
- Trial name
- NCT06232759
- Testing
- Transarterial chemoembolization combined with Tyrosine Kinase Inhibitors and Tislelizumab
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Guangxi Medical University
Non Small Cell Lung Cancer
Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC
A phase II, open-label, multicenter, two cohorts, prospective clinical study to investigate the efficacy and safety of tislelizumab (anti-pd1 antibody) combined with chemotherapy with or without bevacizumab in non-squamous…
- Trial name
- NCT04405674
- Testing
- Tislelizumab, Carboplatin, Pemetrexed
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Chest Hospital
Tislelizumab, Safety
Predictive Biomarker for Efficacy and Safety of Combination of Chemotherapy and Tislelizumab in NSCLC
To explore the related biomarkers for safety and efficacy of the combination of chemotherapy and tislelizumab in non-small cell lung cancer
- Conditions
- Tislelizumab, Safety, Biomarker, Chemotherapy
- Trial name
- NCT05244837
- Testing
- Tislelizumab 200 mg, Carboplatin AUC 5, pemetrexed 500mg/m2
- Where
- 4 sites in China
- Volunteers
- 100 people
- Sponsor
- Hao Long
Solid Tumor
Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BGB-B167 monotherapy and in combination with tislelizumab (BGB-A317) in participants with select advanced solid…
- Trial name
- NCT05494762
- Testing
- BGB-B167, Tislelizumab
- Where
- 8 sites in United States, Australia
- Volunteers
- 55 people
- Sponsor
- BeiGene
Urothelial Carcinoma
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
This is a multicenter, randomized, double-blind, placebo-controlled, Phase 3 study designed to compare the efficacy and safety of tislelizumab + either cisplatin or carboplatin + gemcitabine versus placebo+ either cisplatin or…
- Trial name
- NCT03967977
- Testing
- Tislelizumab, Cisplatin, Gemcitabine Hydrochloride
- Where
- 46 sites in China, Taiwan
- Volunteers
- 420 people
- Sponsor
- BeiGene